Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 91 - 100 of 104

Investigator:

Mathias Jucker

Title:

NfL in CSF of familial AD (DIAN)

Date of Request:

1/7/2016

ID:

DIAN-T1601

Aim 1:

to relate CSF NfL levels to the disease progression in familial AD

Investigator:

Nikolaos Robakis

Title:

Role of PS1 and FAD mutants on neuronal receptor complexes.

Date of Request:

1/25/2016

ID:

DIAN-T1602

Aim 1:

Examine role of PS1 and FAD mutants on neuronal receptor complexes and dimerization

Aim 2:

Examine effects of PS1 and FAD mutants on the neuroprotective activities of BDNF and ephrins

Investigator:

Suzanne Schindler

Title:

Comparison of intra-individual change in INNOTEST CSF biomarkers in Autosomal Dominant Alzheimer Disease and Late Onset Alzheimer Disease

Date of Request:

4/25/2016

ID:

DIAN-T1603

Aim 1:

Aim 1: Characterization of intra-individual CSF biomarker changes

Aim 2:

Aim 2: Correlation of CSF and imaging biomarkers of neurodegeneration

Aim 3:

Aim 3: CSF biomarkers predict cognitive performance

Investigator:

Assistant professor Henrietta M Nielsen, PhD

Title:

CSF alpha-synuclein in familial versus sporadic AD

Date of Request:

5/24/2016

ID:

DIAN-T1604

Aim 1:

To assess CSF alpha-synuclein levels in patients with familial AD versus sporadic AD and controls

Aim 2:

To investigate potential associations between CSF alpha-synuclein levels, AD biomarkers (piB-PET and CSF AD biomarkers) and cognitive status in familiar AD patients

Aim 3:

To investigate potential effects of APOE genotype on CSF alpha-synuclein levels in familial versus sporadic AD patients

Investigator:

Perminder S Sachdev

Title:

Identification and preliminary validation of plasma protein, lipid and metabolite biomarkers in autosomal dominant Alzheimer?s disease

Date of Request:

6/2/2016

ID:

DIAN-T1605

Aim 1:

Identification of plasma protein biomarker candidates using two discovery proteomics approaches (iTRAQ and SWATH-MS)

Aim 2:

Targeted proteomics for validation of protein biomarker candidates and comparison of proteins changes in ADAD and LOAD

Aim 3:

Identification of metabolite biomarkers using targeted and non-targeted metabolomics

Aim 4:

Investigate and validate lipid and metabolite alterations using liquid chromatography coupled with mass spectrometry (LC-MS) in autosomal dominant Alzheimers disease

Investigator:

Mathias Jucker

Title:

Neurofilament light chain in blood serum as marker of disease progression in neurodegenerative diseases

Date of Request:

6/29/2016

ID:

DIAN-T1606

Aim 1:

Determine whether and how many years before the estimated time point of symptom onset (EYO) mutation carriers (MC) of autosomal dominant Alzheimer?s disease (ADAD) show altered blood (serum) levels of neurofilament light chain (NfL) compared to non-mutation carriers (nMC).

Aim 2:

Test whether serum levels of NfL are correlated with previous measured CSF levels and are associated with longitudinal changes in PIB-PET, FDG-PET, and structural MRI, resting state fMRI, with other CSF biomarkers, clinical symptoms and performance

Investigator:

Randall Bateman

Title:

DIAN-ADNI Comparison study

Date of Request:

7/19/2016

ID:

DIAN-T1607

Aim 1:

characterize the stages of preclinical AD with amyloid PET and cerebrospinal fluid (CSF) concentrations of Aβ and tau and phosphorylated tau (p-tau) and determine whether both groups demonstrate initial cerebral amyloidosis that is followed by the development of neurodegeneration prior to onset of A

Aim 2:

In both ADAD and LOAD, determine whether initial symptoms of AD are characterized by subjective reports (self-reported and those of a study partner) of the gradual onset of memory impairment as well as by deficits in objective measures of episodic memory

Aim 3:

In both LOAD and ADAD, determine whether there is a pattern of disease progression that is marked by intra-individual global cognitive and functional decline that culminates in death.

Aim 4:

Characterize other similarities and any differences in AD phenotypes between LOAD and ADAD

Investigator:

Sidney Strickland

Title:

Aβ-specific fibrin fragment resistant to fibrinolysis in the CSF and plasma of familial AD patients with HCHWA

Date of Request:

9/7/2016

ID:

DIAN-T1608

Aim 1:

Analyze the level of fibrin degradation products in the antemortem CSF of HCHWA patients and compare levels to sporadic AD cases and non-demented controls.

Aim 2:

Analyze the level of an A?-specific fibrin fragment resistant to fibrinolysis in the plasma of AD patients with HCHWA and compare levels to sporadic AD cases and non-demented controls.

Investigator:

Alice PEBAY

Title:

Human iPSC-derived organoids to study Alzheimer?s disease

Date of Request:

9/9/2016

ID:

DIAN-T1609

Aim 1:

to generate cortical organoids from iPSCs of AD patients and controls

Aim 2:

to generate iPSCs from APP mutation fibroblasts

Aim 3:

To study pathological events of AD in organoids

Investigator:

Dr. A Claudio Cuello

Title:

Investigating early NGF dysmetabolism as a source of novel biomarkers in ?silent? stages of Alzheimer?s disease

Date of Request:

9/23/2016

ID:

DIAN-T1610

Aim 1:

To investigate plasma markers of NGF dysmetabolism as a source of biomarkers in pre-clinical AD

Aim 2:

To investigate CSF markers of NGF dysmetabolism as a source of biomarkers in pre-clinical AD